New combo therapy shows promise in kidney cancer fight

NCT ID NCT03203473

First seen Feb 06, 2026 · Last updated May 15, 2026 · Updated 17 times

Summary

This study tested two immunotherapy drugs, nivolumab and ipilimumab, in 85 adults with advanced kidney cancer that could not be removed by surgery. The goal was to see if adding ipilimumab could turn non-responding tumors into shrinking ones, and how long any response lasted after stopping nivolumab. The approach aims to better control the disease, not cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02115, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02115, United States

  • Lifespan Comprehensve Cancer Center

    Providence, Rhode Island, 02903, United States

  • University of California, San Diego Moores Cancer Center

    La Jolla, California, 92093, United States

  • University of Chicago Medical Center

    Chicago, Illinois, 60637, United States

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina, 27599, United States

  • University of Utah, Huntsman Cancer Center

    Salt Lake City, Utah, 84112, United States

  • Unviersity of Wisconsin Carbone Cancer Center

    Madison, Wisconsin, 53792, United States

Conditions

Explore the condition pages connected to this study.